首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Clinical cancer research

缩写:CLIN CANCER RES

ISSN:1078-0432

e-ISSN:1557-3265

IF/分区:10.9/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引11950条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Kiwan Kim,Seong-Won Song,Yeongha Jeon et al. Kiwan Kim et al.
Purpose: This single-center, open-label, Phase 1 trial evaluated the safety and tolerability of chimeric antigen receptor (CAR)-T cells targeting interleukin-13 receptor α2 (IL13Rα2) in patients with malignant gliomas. ...
Hildur Helgadottir,Mariaelena Capone,Laura Ridolfi et al. Hildur Helgadottir et al.
Purpose: While immune checkpoint inhibitors (ICI) are generally the preferred first-line treatment for metastatic BRAF V600-mutated melanoma, a subgroup that remains incompletely defined requires initial tumor control wit...
Naing Lin Shan,Henriette Balinda,Jiawei Dai et al. Naing Lin Shan et al.
Purpose: Increased dependence on de novo fatty acid synthesis is a key feature of metabolic rewiring in cancer cells. Acetyl-CoA-carboxylase (ACC) is the rate limiting enzyme of de novo fatty acid synthesis. We examined t...
Lewis Au,Jeanne Tie Lewis Au
Circulating tumor DNA (ctDNA) profiling detects actionable genomic alterations in advanced biliary tract cancer faster (8 vs 27 days) and more often (90% vs 50%) than tissue, with high concordance. A recent retrospective study establishes c...
Xuqi Sun,Wanwan Gao,Chunhui Shou et al. Xuqi Sun et al.
Purpose: Treatment options for advanced hepatocellular carcinoma (HCC) remain limited, and responses to later-line therapies are modest. Glypican-3 (GPC3), highly expressed in HCC but rarely in normal tissues, is an attra...
Carla Saoud,Chad Vanderbilt,Jamal Benhamida et al. Carla Saoud et al.
Introduction: Microsatellite instability (MSI) has broad biologic and clinical relevance across solid tumors, yet its role in sarcomas remains poorly defined. We delineate the clinicopathologic, molecular, and treatment-r...
Shuang G Zhao,Erik Holmberg,Dan Lundstedt et al. Shuang G Zhao et al.
Purpose: PORTOS is a 24-gene radiation response signature developed and validated in multiple randomized trials in prostate cancer. Given its basis in general radiation and DNA damage response pathways, we sought to evalu...
Elena Palassini,Sara Pizzamiglio,Emanuela Palmerini et al. Elena Palassini et al.
Objective: The ISG-STS 1001 was an international, randomized, phase III, trial for localized, high-risk, STS comparing neoadjuvant ChT with epirubicin and ifosfamide (EI) versus a histology-tailored regimen. The trial inc...
Kenichi Harano,Takehiro Nakao,Shin Nishio et al. Kenichi Harano et al.
Purpose: Preclinical studies suggest that poly(ADP-ribose) polymerase (PARP) inhibition enhances tumor immunogenicity through STING pathway activation, providing rationale for combination with immune checkpoint inhibitors...